Last reviewed · How we verify
glycopyrronium Topical Wipes
glycopyrronium Topical Wipes is a Anticholinergic agent / Antiperspirant Small molecule drug developed by Journey Medical Corporation. It is currently in Phase 3 development for Primary hyperhidrosis (excessive sweating). Also known as: DRM04.
Glycopyrronium is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce sweat gland secretion.
Glycopyrronium is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce sweat gland secretion. Used for Primary hyperhidrosis (excessive sweating).
At a glance
| Generic name | glycopyrronium Topical Wipes |
|---|---|
| Also known as | DRM04 |
| Sponsor | Journey Medical Corporation |
| Drug class | Anticholinergic agent / Antiperspirant |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Glycopyrronium works by antagonizing muscarinic M3 receptors on eccrine sweat glands, thereby decreasing acetylcholine-mediated sweat production. When applied topically as a wipe formulation, it provides localized antiperspirant effects without significant systemic absorption. This mechanism makes it suitable for treating hyperhidrosis (excessive sweating) in specific body areas.
Approved indications
- Primary hyperhidrosis (excessive sweating)
Common side effects
- Dry skin
- Irritation at application site
- Pruritus
Key clinical trials
- Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis (PHASE2)
- Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis (PHASE3)
- Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis (PHASE3)
- Study of Glycopyrronium in Axillary Hyperhydrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glycopyrronium Topical Wipes CI brief — competitive landscape report
- glycopyrronium Topical Wipes updates RSS · CI watch RSS
- Journey Medical Corporation portfolio CI
Frequently asked questions about glycopyrronium Topical Wipes
What is glycopyrronium Topical Wipes?
How does glycopyrronium Topical Wipes work?
What is glycopyrronium Topical Wipes used for?
Who makes glycopyrronium Topical Wipes?
Is glycopyrronium Topical Wipes also known as anything else?
What drug class is glycopyrronium Topical Wipes in?
What development phase is glycopyrronium Topical Wipes in?
What are the side effects of glycopyrronium Topical Wipes?
What does glycopyrronium Topical Wipes target?
Related
- Drug class: All Anticholinergic agent / Antiperspirant drugs
- Target: All drugs targeting Muscarinic M3 receptor
- Manufacturer: Journey Medical Corporation — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Primary hyperhidrosis (excessive sweating)
- Also known as: DRM04
- Compare: glycopyrronium Topical Wipes vs similar drugs
- Pricing: glycopyrronium Topical Wipes cost, discount & access